|Articles|April 15, 2002
Potential treatment: Miravant regains rights to wet AMD therapy
Santa Barbara, CA-Miravant Medical Technologies plans to seek new applications for its primary drug candidate, a potential therapy for wet age-related macular degeneration (AMD)
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Advancements in laser refractive surgery
2
From then to next: Five decades of transformation in ophthalmology
3
Optigo: Lead anti-VEGF program advancing toward IND-enabling studies
4
Q&A: Advancing a long-acting anti-VEGF candidate: What it means for retinal disease
5














































.png)


